Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application
Roberto Mina(Emory University), Elena Zamagni(Istituto di Ematologia di Bologna), Sônia Maria Coelho Móre(Marche Polytechnic University), Antonio Giovanni Solimando(University of Parma), Carmine Liberatore(Arcispedale Sant'Anna), Gregorio Barilà(University of Padua), Elisabetta Antonioli(Azienda Ospedaliero-Universitaria Careggi), Anna Furlan(AULSS 2 Marca Trevigiana), Elona Saraci(University of Turin), Bernardo Rossini(Istituto Tumori Bari), Marina Castellain Martello(Istituto di Ematologia di Bologna), Cirino Botta(University of Palermo), Paola Storti(University of Parma), Stefania Oliva(Piedmont Reference Center for Epidemiology and Cancer Prevention), Niccolò Bolli(University of Milan)
Cited by 1
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|653
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540